Insider Selling: Amgen (NASDAQ:AMGN) SVP Sells 2,970 Shares of Stock

Key Points

• Amgen SVP Nancy Grygiel sold 2,970 shares at an average price of $402.16, generating approximately $1.19 million. The transaction reduced her ownership by 28.81%, leaving her with 7,340 shares.
• Amgen reported quarterly EPS of $6.29 and revenue of $10.05 billion, exceeding analyst expectations, while revenue increased 9.5% year over year. The company set fiscal 2026 EPS guidance at $22.30–$23.50.
• Shares rose 1.5% to $410.95, near the 52-week high, and Amgen announced a quarterly dividend of $2.52 per share, equivalent to a 2.5% annualized yield. Analysts remain mixed, with the stock carrying a consensus “Hold” rating.

Amgen Inc. (NASDAQ:AMGN - Get Free Report) SVP Nancy Grygiel sold 2,970 shares of the company's stock in a transaction on Thursday, August 6th. The shares were sold at an average price of $402.16, for a total value of $1,194,415.20. Following the completion of the sale, the senior vice president owned 7,340 shares of the company's stock, valued at approximately $2,951,854.40. The trade was a 28.81% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.

Amgen Trading Up 1.5%

Shares of AMGN traded up $6.10 during midday trading on Friday, reaching $410.95. The company had a trading volume of 1,821,460 shares, compared to its average volume of 2,750,778. Amgen Inc. has a 1-year low of $269.77 and a 1-year high of $418.40. The company has a quick ratio of 1.01, a current ratio of 1.37 and a debt-to-equity ratio of 4.44. The firm has a 50 day simple moving average of $361.29 and a 200-day simple moving average of $355.86. The stock has a market cap of $221.79 billion, a PE ratio of 25.54, a price-to-earnings-growth ratio of 4.10 and a beta of 0.41.

Amgen (NASDAQ:AMGN - Get Free Report) last released its quarterly earnings data on Tuesday, August 4th. The medical research company reported $6.29 earnings per share (EPS) for the quarter, topping the consensus estimate of $5.62 by $0.67. Amgen had a net margin of 22.95% and a return on equity of 124.14%. The firm had revenue of $10.05 billion during the quarter, compared to analysts' expectations of $9.43 billion. During the same period last year, the business earned $6.02 earnings per share. Amgen's revenue was up 9.5% compared to the same quarter last year. Amgen has set its FY 2026 guidance at 22.300-23.500 EPS. Research analysts forecast that Amgen Inc. will post 22.47 EPS for the current fiscal year.

Amgen Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, September 11th. Investors of record on Friday, August 21st will be given a $2.52 dividend. This represents a $10.08 annualized dividend and a yield of 2.5%. The ex-dividend date is Friday, August 21st. Amgen's dividend payout ratio is presently 70.15%.

More Amgen News

Here are the key news stories impacting Amgen this week:

• Positive Sentiment: Quarterly results exceeded expectations: Amgen reported second-quarter revenue of approximately $10.05 billion, up 9.5% year over year, while adjusted earnings of $6.29 per share surpassed the $5.62 consensus estimate. Amgen Q2 2026 earnings beat, raises full-year outlook, drops AMG 513
• Positive Sentiment: Guidance was raised: Management now expects fiscal-year earnings of $22.30 to $23.50 per share, supported by growth in cardiovascular, bone-health and rare-disease medicines. The performance offset pressure in the bone-health business and the decision to discontinue obesity candidate AMG 513. Amgen Stock Climbs as Drug Growth Outruns Obesity Setback
• Positive Sentiment: Analyst targets point to additional upside: BMO Capital Markets raised its target to $450, while UBS and TD Cowen set targets of $440 and $452, respectively. Morgan Stanley, RBC, Oppenheimer and Scotiabank also indicated that Amgen’s stock could rise. BMO Capital Markets Boosts Amgen Price Target to $450
• Neutral Sentiment: Analyst sentiment remains mixed: Wells Fargo raised its target to $400 and Canaccord Genuity to $384, both below the stock’s recent trading level, while Citi maintained a Hold rating and UBS maintained a Buy rating. This suggests strong results have improved sentiment, but valuation and pipeline execution remain concerns. Citi Keeps Their Hold Rating on Amgen
• Negative Sentiment: Pipeline disappointment limits the upside case: Amgen dropped AMG 513, its obesity-drug candidate, removing a potential growth driver and leaving investors focused on the company’s existing medicines and remaining pipeline. Amgen drops AMG 513

Analyst Ratings Changes

Several equities analysts have recently commented on the company. Erste Group Bank reaffirmed a "hold" rating on shares of Amgen in a research note on Tuesday, May 5th. Bank of America boosted their price objective on shares of Amgen from $312.00 to $317.00 and gave the company an "underperform" rating in a report on Wednesday. Barclays increased their target price on shares of Amgen from $350.00 to $360.00 and gave the stock an "equal weight" rating in a research note on Wednesday, July 29th. Wells Fargo & Company lifted their price target on shares of Amgen from $390.00 to $400.00 and gave the company an "equal weight" rating in a research report on Wednesday. Finally, Daiwa Securities Group decreased their price objective on shares of Amgen from $410.00 to $390.00 and set an "outperform" rating on the stock in a report on Wednesday, May 13th. One investment analyst has rated the stock with a Strong Buy rating, twelve have given a Buy rating, fifteen have issued a Hold rating and three have assigned a Sell rating to the stock. Based on data from MarketBeat, Amgen currently has an average rating of "Hold" and an average price target of $370.07.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently made changes to their positions in AMGN. Norges Bank purchased a new position in Amgen in the fourth quarter valued at $2,164,162,000. Capital World Investors boosted its position in shares of Amgen by 22.9% during the 4th quarter. Capital World Investors now owns 23,097,711 shares of the medical research company's stock worth $7,560,249,000 after acquiring an additional 4,302,237 shares in the last quarter. BlackRock Inc. raised its position in shares of Amgen by 4.8% during the 2nd quarter. BlackRock Inc. now owns 49,362,016 shares of the medical research company's stock worth $17,874,974,000 after acquiring an additional 2,261,544 shares in the last quarter. State Street Corp raised its position in shares of Amgen by 4.4% during the 4th quarter. State Street Corp now owns 30,591,403 shares of the medical research company's stock worth $10,012,872,000 after acquiring an additional 1,287,310 shares in the last quarter. Finally, Geode Capital Management LLC lifted its stake in Amgen by 7.8% during the fourth quarter. Geode Capital Management LLC now owns 14,303,294 shares of the medical research company's stock worth $4,665,822,000 after purchasing an additional 1,035,779 shares during the last quarter. Hedge funds and other institutional investors own 76.50% of the company's stock.

About Amgen

Amgen Inc NASDAQ: AMGN is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen's work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen's commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source